Xytronyx Inc. completes $10 million private placement and announces other significant events.SAN DIEGO--(BUSINESS WIRE)--March 7, 1997--Xytronyx Inc. (ASE (Adaptive Server Enterprise) A relational DBMS from Sybase that runs on Windows NT/2000, Linux and a variety of Unix platforms. ASE is a comprehensive and robust data management product with a long history dating back to the late 1980s. :XYX) announced that it completed its previously announced sale of $10 million of Premium Preferred Units, including $3,345,000 raised on Dec. 19, 1996, resulting in aggregate net proceeds Net Proceeds
The amount received after all costs are deducted from the sale of a piece of property or security.
In the case of an investor selling a security, net proceeds represent the proceeds from the sale minus any trading costs (i.e. commissions). of $8.7 million.
The company also announced that a successful animal study suggests in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body.
Within a living organism.
in vivo adv. proof of principle for its Photodynamic Immunotherapy (PDIT PDIT Professional Development Institute of Tourism (Parksville, British Columbia, Canada)
PDIT Product Data Integration Technologies
PDIT Photographic Digital Imaging Technician
PDIT Proudha Devaraya Institute of Technology ) for the treatment of metastatic Metastatic
The term used to describe a secondary cancer, or one that has spread from one area of the body to another.
Mentioned in: Coagulation Disorders
pertaining to or of the nature of a metastasis. breast cancer.
In addition, together with Binary Therapeutics Inc. (BTI BTI Beverage Testing Institute
BTI Boyce Thompson Institute
BTI British American Tobacco (stock symbol)
BTI Boston Theological Institute
Bti Bacillus Thuringiensis Israelensis
BTI BioTechnology Institute
BTI Binding Tariff Information ), Xytronyx has agreed to extend the option period during which Xytronyx may elect to consummate the merger with BTI, the holder of certain photodynamic-therapy technology.
Xytronyx intends to use the net proceeds for the repayment of past-due accrued liabilities of approximately $2 million, continued development of its products, working capital and for general corporate purposes.
``The consummation of this private placement represents an important milestone for the company,'' said Dr. H. Laurence Shaw, the recently appointed chief executive officer of Xytronyx. ``Xytronyx will now have a solid opportunity to realize its potential as the company's products continue to progress.''
Results of the PDIT animal study were presented at the BiOS '97 International Biomedical bi·o·med·i·cal
1. Of or relating to biomedicine.
2. Of, relating to, or involving biological, medical, and physical sciences. Optics Symposium by the principal investigators, Wei Chen of the University of Oklahoma University of Oklahoma, abbreviated OU, is a coeducational public research university located in the U.S. state of Oklahoma. Founded in 1890, it existed in Oklahoma Territory near Indian Territory 17 years before the two became the state of Oklahoma. and the Oklahoma School of Science and Mathematics The Oklahoma School of Science and Mathematics (OSSM) is a two-year residential public high school located in Oklahoma City, Oklahoma. Established by the Oklahoma legislature in 1983, the school was designed to educate academically gifted high school students in advanced and Robert E. Nordquist of Wound Healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by of Oklahoma.
They cited from their paper, titled, ``Laser-tissue Photobiological Interaction: A New Mechanism for Laser-Sensitizer- Immunoadjuvant Treatment of Metastatic Cancers'' (W.R. Chen, et al.).
PDIT treatment, proprietary to Xytronyx, consists of the co-injection of an infrared absorbing dye (photosensitizing photosensitizing
some plants carry primary photodynamic agents, e.g. Hypericum perforatum. drug) and an immuno-adjuvant directly into a tumor followed by illumination with an infrared laser.
In the cited rat metastatic breast-cancer model, PDIT treatment resulted in a significant impact on the long-term survival rate of the rats and improved their ability to resist a tumor rechallenge. PDIT treatment is in preparation for human clinical trials and may initially target breast cancer.
Xytronyx believes that the potential of PDIT therapy to destroy metastatic tumors offers an improved methodology for treatment of cancers such as breast, lung and prostate, particularly when the cancer is in the more advanced stages.
``We are excited about the potential PDIT treatment could ultimately have for the thousands of women who are diagnosed and undergo treatment for breast cancer each year,'' said David A. Okrongly, Ph.D., vice president of research and development at Xytronyx.
``Our PDIT treatment, which involves a laser-tissue interaction and an induced immune response immune response
An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. , may prove to be crucial to the treatment of various cancers.''
``Photophysical reactions, which are both short-term and localized in action, have been the focus of laser-tissue interactions,'' noted Shaw.
``Our experimental results on the treatment of implanted mammary tumors indicate that a systemic, long-term positive response against these tumors was stimulated by our PDIT therapy. Needless to say, we are enthusiastic about these results.'' No assurance can be given that the drug will be approved by the FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. or receive market acceptance.
Xytronyx also announced that it and BTI have agreed to extend the period during which Xytronyx may acquire BTI from April 30, 1997, until such time as BTI has completed human clinical trials of boronated porphyrin compounds (BOPP) at an agreed-upon dose level.
The option period was extended at Xytronyx's request to enable BTI to complete clinical studies, to commence clinical trials in humans and to demonstrate that a given dose level of BOPP in humans would not cause certain adverse events.
The extension of the option should give Xytronyx greater opportunity to assess the preliminary data resulting from the BOPP preclinical trials and the Phase I human clinical trials before determining whether to acquire BTI, and to evaluate the possibility of adverse events in human patients.
No assurance can be given that Xytronyx will exercise its option. In this connection, Xytronyx has determined to defer exercise of the option and the shareholder vote in connection therewith.
Shaw commented: ``This additional time will allow Xytronyx to make a thorough evaluation of the data. The company remains excited about the opportunity that the BOPP technology could offer Xytronyx, especially when developed in addition to the PDIT technology.''
The closing of $10 million was the final closing in a private placement of units at a price per unit of $100,000, representing the maximum number of units offered in the private placement.
Each unit consisted of 500 shares of preferred stock Stock shares that have preferential rights to dividends or to amounts distributable on liquidation, or to both, ahead of common shareholders.
Preferred stock is given preference over common stock. Holders of preferred stock receive dividends at a fixed annual rate. , par value $25 per share, stated value Stated Value
A value that, instead of being par value, is assigned to a corporation's stock for accounting purposes. Stated value has no relation to market price.
Notes: $200 per share, and 50,000 common-stock purchase warrants to accredited individuals and institutional investors pursuant to Regulation D under the Securities Act of 1933, as amended.
The 25 unit over-allotment option was not exercised. Each share of preferred stock may be converted at the option of the holder into 208.3333 shares of common stock.
The conversion price is subject to adjustment on the date which is 12 months after the final closing date if the average closing bid price of the common stock for the 30 consecutive trading days immediately preceding that date is less than 130 percent of the conversion price as adjusted, subject to a limit on the number of shares that may be issued pursuant to such reset.
Each warrant entitles the holder to purchase one share of common stock at a price of $1 per share and may be exercised until Nov. 26, 2005. Paramount Capital Inc., a New York-based investment banking firm, acted as placement agent to Xytronyx on the private placement.
Xytronyx has been informed that it is out of compliance with certain listing requirements Listing requirements
Requirements, including minimum shares outstanding, market value, and income, that are laid down by an exchange for any stock to be listed for trading. of the American Stock Exchange American Stock Exchange (AMEX)
Stock exchange in the U.S. Originally known as “the Curb,” it began as an outdoor marketplace in New York City c. 1850. It moved indoors to its present location in the Wall Street area in 1921. because of its record of losses, cash outflows, reduced shareholders' equity and impaired financial condition. Xytronyx is in discussions with the Exchange regarding its condition; however, there can be no assurance the listing will be continued.
As with any company developing novel therapeutics, Xytronyx may make certain forward-looking statements that relate to future business and financial performance, including the statements made in this news release.
Such statements can only be predictions and the actual events or future results may differ from those discussed and from Xytronyx's expectations, due, among other things, to those risks described in Xytronyx's reports on Form 10-Q for the quarter ended Dec. 31, 1996, and in its Form 10-K.
CONTACT: Xytronyx Inc., San Diego
Jim Hertzog, 619/550-3900